Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC + Pembrolizumab in Advanced Melanoma Post-PD-1
NCT04068181Phase 2Completed
- Sponsor
- Amgen
- Start
- Jan 2020
- Primary completion
- Aug 2021
- Modality
- Oncolytic Viruses
- Countries
- 11
01
Overview
A Phase 2 trial of talimogene laherparepvec in melanoma, sponsored by Amgen. Started Jan 2020; status: completed.
02
Drugs
talimogene laherparepvec
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04068181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04068181.